Dixon Mitchell Investment Counsel Inc. Novartis Ag Transaction History

Dixon Mitchell Investment Counsel Inc.

$2.2 Trillion
Q3 2024

40 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 11, 2024	BUY	$92.57 - $107.37 $1,481 - $1,717	16 New	16 $1.7 Million
Q3 2021 Jan 17, 2024	SELL	$81.78 - $95.14 $8.44 Million - $9.82 Million	-103,207 Closed	0 $0
Q2 2021 Jan 17, 2024	SELL	$85.24 - $94.15 $9,120 - $10,074	-107 Reduced 0.1%	103,207 $9.42 Billion
Q1 2021 Jan 17, 2024	BUY	$83.5 - $98.47 $1.03 Million - $1.21 Million	12,288 Added 13.5%	103,314 $8.83 Billion
Q4 2020 Jan 17, 2024	SELL	$78.07 - $94.43 $10,305 - $12,464	-132 Reduced 0.14%	91,026 $8.6 Billion
Q3 2020 Jan 17, 2024	BUY	$82.14 - $91.0 $3.38 Million - $3.75 Million	41,200 Added 82.47%	91,158 $7.93 Billion
Q2 2020 Jan 17, 2024	BUY	$80.93 - $91.1 $203,134 - $228,661	2,510 Added 5.29%	49,958 $4.36 Billion
Q1 2020 Jan 17, 2024	SELL	$70.67 - $99.01 $290,665 - $407,228	-4,113 Reduced 7.98%	47,448 $3.91 Billion
Q4 2019 Jan 17, 2024	BUY	$84.35 - $95.37 $89,157 - $100,806	1,057 Added 2.09%	51,561 $4.88 Billion
Q3 2019 Jan 17, 2024	SELL	$85.54 - $94.26 $31,222 - $34,404	-365 Reduced 0.72%	50,504 $4.39 Billion
Q2 2019 Jan 17, 2024	BUY	$75.4 - $92.8 $91,309 - $112,380	1,211 Added 2.44%	50,869 $4.64 Billion
Q1 2019 Jan 17, 2024	SELL	$75.32 - $86.15 $3.84 Million - $4.39 Million	-50,967 Reduced 50.65%	49,658 $4.77 Billion
Q4 2018 Jan 17, 2024	SELL	$73.66 - $82.02 $100,324 - $111,711	-1,362 Reduced 1.34%	100,625 $8.63 Billion
Q3 2018 Jan 17, 2024	BUY	$66.94 - $77.43 $49,937 - $57,762	746 Added 0.74%	101,987 $8.79 Billion
Q2 2018 Jan 17, 2024	BUY	$64.91 - $73.36 $96,001 - $108,499	1,479 Added 1.48%	101,241 $7.65 Billion
Q1 2018 Jan 17, 2024	BUY	$70.39 - $84.15 $261,287 - $312,364	3,712 Added 3.86%	99,762 $8.07 Billion
Q4 2017 Jan 17, 2024	BUY	$72.33 - $77.64 $485,985 - $521,663	6,719 Added 7.52%	96,050 $8.06 Billion
Q3 2017 Jan 17, 2024	SELL	$74.14 - $77.27 $40,999 - $42,730	-553 Reduced 0.62%	89,331 $7.67 Billion
Q2 2017 Jan 17, 2024	BUY	N/A	1,265 Added 1.43%	89,884 $7.5 Billion
Q1 2017 Jan 17, 2024	BUY	N/A	15,252 Added 20.79%	88,619 $6.58 Billion
Q4 2016 Jan 17, 2024	BUY	N/A	3,780 Added 5.43%	73,367 $5.34 Billion
Q3 2016 Jan 17, 2024	BUY	N/A	4,725 Added 7.28%	69,587 $5.49 Billion
Q2 2016 Jan 17, 2024	BUY	N/A	2,317 Added 3.7%	64,862 $5.35 Billion
Q1 2016 Jan 17, 2024	BUY	N/A	851 Added 1.38%	62,545 $4.53 Billion
Q4 2015 Jan 17, 2024	BUY	N/A	3,297 Added 5.65%	61,694 $5.31 Billion
Q3 2015 Jan 17, 2024	BUY	N/A	1,331 Added 2.33%	58,397 $5.37 Billion
Q2 2015 Jan 17, 2024	BUY	N/A	917 Added 1.63%	57,066 $5.61 Billion
Q1 2015 Jan 17, 2024	BUY	N/A	20,940 Added 59.47%	56,149 $5.54 Billion
Q3 2014 Jan 17, 2024	BUY	N/A	752 Added 2.18%	35,209 $3.31 Billion
Q2 2014 Jan 17, 2024	BUY	N/A	1,339 Added 4.04%	34,457 $3.12 Billion
Q1 2014 Jan 17, 2024	BUY	N/A	2,985 Added 9.91%	33,118 $2.82 Billion
Q4 2013 Jan 17, 2024	BUY	N/A	1,841 Added 6.51%	30,133 $2.42 Billion
Q3 2013 Jan 17, 2024	BUY	N/A	5,780 Added 25.68%	28,292 $2.17 Billion
Q2 2013 Jan 17, 2024	BUY	N/A	3,747 Added 19.97%	22,512 $1.59 Billion
Q1 2013 Jan 17, 2024	SELL	N/A	-6,430 Reduced 25.52%	18,765 $1.34 Billion
Q4 2012 Jan 17, 2024	BUY	N/A	620 Added 2.52%	25,195 $1.59 Billion
Q3 2012 Jan 17, 2024	BUY	N/A	1,525 Added 6.62%	24,575 $1.51 Billion
Q2 2012 Jan 17, 2024	BUY	N/A	1,220 Added 5.59%	23,050 $1.29 Billion
Q1 2012 Jan 17, 2024	BUY	N/A	15,310 Added 234.82%	21,830 $1.21 Billion
Q4 2011 Jan 17, 2024	BUY	N/A	6,520	6,520 $373 Million

Others Institutions Holding NVS

# of Institutions

1,434

Shares Held

138M

Call Options Held

1.48M

Put Options Held

1.55M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $230B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dixon Mitchell Investment Counsel Inc., based on Form 13F filings with the SEC.

News

Stay updated on Dixon Mitchell Investment Counsel Inc. with notifications on news.

Account